Compare AP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AP | MOLN |
|---|---|---|
| Founded | 1929 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Fluid Controls | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 158.9M |
| IPO Year | N/A | 2021 |
| Metric | AP | MOLN |
|---|---|---|
| Price | $8.99 | $4.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 328.8K | 2.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $285.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $3.36 |
| 52 Week High | $9.55 | $5.11 |
| Indicator | AP | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.40 | 67.30 |
| Support Level | $2.39 | $3.50 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.78 | 0.17 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 80.94 | 75.73 |
Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.